NasdaqGS:CCXI

Stock Analysis Report

Executive Summary

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States.

Snowflake

Fundamentals

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has ChemoCentryx's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.0%

CCXI

1.6%

US Biotechs

0.4%

US Market


1 Year Return

-32.2%

CCXI

-7.7%

US Biotechs

6.9%

US Market

Return vs Industry: CCXI underperformed the US Biotechs industry which returned -7.7% over the past year.

Return vs Market: CCXI underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

CCXIIndustryMarket
7 Day2.0%1.6%0.4%
30 Day3.2%-2.9%-1.1%
90 Day-6.6%-1.7%-0.5%
1 Year-32.2%-32.2%-6.9%-7.7%9.3%6.9%
3 Year23.8%23.8%14.7%10.7%45.8%36.4%
5 Year35.3%35.3%-2.3%-7.0%62.9%45.1%

Price Volatility Vs. Market

How volatile is ChemoCentryx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ChemoCentryx undervalued compared to its fair value and its price relative to the market?

6.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate CCXI's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate CCXI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CCXI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CCXI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate CCXI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CCXI is overvalued based on its PB Ratio (6.3x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is ChemoCentryx forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-10.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CCXI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CCXI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CCXI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CCXI's revenue (36.9% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: CCXI's revenue (36.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: CCXI is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has ChemoCentryx performed over the past 5 years?

21.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CCXI is unprofitable, but has reduced losses over the past 5 years at a rate of 21.3% per year.

Accelerating Growth: Unable to compare CCXI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CCXI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: CCXI has a negative Return on Equity (-68.25%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CCXI is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CCXI is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is ChemoCentryx's financial position?


Financial Position Analysis

Short Term Liabilities: CCXI's short term assets ($202.0M) exceeds its short term liabilities ($56.7M)

Long Term Liabilities: CCXI's short term assets (202.0M) exceeds its long term liabilities (101.7M)


Debt to Equity History and Analysis

Debt Level: CCXI's debt to equity ratio (27.6%) is considered satisfactory

Reducing Debt: CCXI's debt to equity ratio has increased from 0.08% to 27.6% over the past 5 years.


Balance Sheet

Inventory Level: CCXI has a low level of unsold assets or inventory.

Debt Coverage by Assets: CCXI's debt is covered by short term assets (assets are 10.234210x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CCXI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CCXI has sufficient cash runway for 1.998296 years if free cash flow continues to reduce at historical rates of -74.2% each year.


Next Steps

Dividend

What is ChemoCentryx's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CCXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CCXI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CCXI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CCXI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CCXI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of ChemoCentryx's salary, the management and board of directors tenure and is there insider trading?

3.2yrs

Average management tenure


CEO

Thomas Schall (60yo)

22.8yrs

Tenure

US$3,862,225

Compensation

Dr. Thomas J. Schall, Ph.D. Founded ChemoCentryx Inc. in November 1996 and has been its Chief Executive Officer and President since 1997. Dr. Schall focuses on the discovery and development of chemokine-ba ...


CEO Compensation Analysis

Compensation vs. Market: Thomas's total compensation ($USD3.86M) is about average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.2yrs

Average Tenure

57yo

Average Age

Experienced Management: CCXI's management team is considered experienced (3.2 years average tenure).


Board Age and Tenure

7.4yrs

Average Tenure

63yo

Average Age

Experienced Board: CCXI's board of directors are considered experienced (7.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$85,845,42102 Nov 18
Vifor Pharma AG
EntityCompany
Shares7,343,492
Max PriceUS$11.69

Ownership Breakdown


Management Team

  • Susan Kanaya (56yo)

    Executive VP

    • Tenure: 3yrs
    • Compensation: US$1.73m
  • Thomas Schall (60yo)

    Founder

    • Tenure: 22.8yrs
    • Compensation: US$3.86m
  • Markus Cappel (58yo)

    Senior VP

    • Tenure: 15.2yrs
    • Compensation: US$1.24m
  • Rajinder Singh (52yo)

    Senior VP & Head of Pharmaceutics

    • Tenure: 3.4yrs
    • Compensation: US$900.75k
  • Cass Kelleher

    Senior Vice President of Clinical Development

    • Tenure: 0.5yrs
  • Dalia Rayes

    Senior VP & Head of Commercial

    • Tenure: 0.8yrs

Board Members

  • Hank McKinnell (76yo)

    Director

    • Tenure: 3yrs
    • Compensation: US$287.70k
  • Jim Tyree (66yo)

    Director

    • Tenure: 7.3yrs
    • Compensation: US$302.70k
  • Joe Feczko (70yo)

    Director

    • Tenure: 7.5yrs
    • Compensation: US$287.70k
  • Edward Mocarski

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Craig Gerard

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Thomas Schall (60yo)

    Founder

    • Tenure: 22.8yrs
    • Compensation: US$3.86m
  • Henry Showell

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Richard Ransohoff

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Thomas Edwards (60yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$294.49k
  • Geoff Parker (54yo)

    Director

    • Tenure: 9.8yrs
    • Compensation: US$267.70k

Company Information

ChemoCentryx, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ChemoCentryx, Inc.
  • Ticker: CCXI
  • Exchange: NasdaqGS
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$450.857m
  • Shares outstanding: 58.25m
  • Website: https://www.chemocentryx.com

Number of Employees


Location

  • ChemoCentryx, Inc.
  • 850 Maude Avenue
  • Mountain View
  • California
  • 94043
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CCXINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2012
2CXDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2012

Biography

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and che ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 00:18
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.